Advertisement

Treatment of Resistant Hypertension. Which Additional Antihypertensive Drugs?

  • Michel Burnier
  • Antoinette Pechère Bertschi
  • Gregoire Wuerzner
Chapter

Abstract

Inadequate antihypertensive therapy is a frequent cause of resistant hypertension. In addition to a poor adherence to drug therapy, inadequate dosages, inappropriate drug combinations, drug interactions, and intolerance to some medications belong to the most common reasons why blood pressure remains uncontrolled in some hypertensive patients. An important issue in drug therapy of refractory hypertension is the type and dose of diuretics. Adapting the dose of diuretic and combining diuretics may help to improve blood pressure control. Moreover, recent studies have suggested that the addition of aldosterone receptor antagonists is an effective therapeutic to normalize blood pressure in patients with resistant hypertension. Thus, before considering a costly search for secondary hypertension or renal denervation, a careful assessment of drug therapy should be performed.

Keywords

Resistant hypertension Medical therapy Drug adherence Diuretics Aldosterone antagonists 

References

  1. 1.
    Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Boudier HA, Zanchetti A (2007) ESH-ESC task force on the management of arterial hypertension. 2007 ESH-ESC practice guidelines for the management of arterial hypertension: ESH-ESC task force on the management of arterial hypertension. J Hypertens 25(9):1751–1762PubMedCrossRefGoogle Scholar
  2. 2.
    Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ (2003) National heart, lung, and blood institute joint national committee on prevention, detection, evaluation, and treatment of high blood pressure; national high blood pressure education program coordinating committee: the seventh report of the joint national committee on prevention, detection, evaluation and treatment of high blood pressure: the JNC 7 report. JAMA 289:2560–2571PubMedCrossRefGoogle Scholar
  3. 3.
    Law MR, Wald NJ, Morris JK, Jordan RE (2003) Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 326:1427PubMedCrossRefGoogle Scholar
  4. 4.
    Yakovlevitch M, Black HR (1991) Resistant hypertension in a tertiary care clinic. Arch Intern Med 151:1786–1792PubMedCrossRefGoogle Scholar
  5. 5.
    Setaro JF, Black HR (1992) Refractory hypertension. N Engl J Med 327:543–547PubMedCrossRefGoogle Scholar
  6. 6.
    Meredith PA (1999) Trough: peak ratio and smoothness index for antihypertensive agents. Blood Press Monit 4(5):257–262PubMedGoogle Scholar
  7. 7.
    Burnier M, Brede Y, Lowy A (2011) Impact of prolonged antihypertensive duration of action on predicted clinical outcomes in imperfectly adherent patients: comparison of aliskiren, irbesartan and ramipril. Int J Clin Pract 65(2):127–133PubMedCrossRefGoogle Scholar
  8. 8.
    Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ (2009) Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med 122(3):290–300PubMedCrossRefGoogle Scholar
  9. 9.
    Azizi M, Guyene TT, Chatellier G, Ménard J (1997) Pharmacological demonstration of the additive effects of angiotensin-converting enzyme inhibition and angiotensin II antagonism in sodium depleted healthy subjects. Clin Exp Hypertens 19(5–6):937–951PubMedCrossRefGoogle Scholar
  10. 10.
    Azizi M, Ménard J, Bissery A, Guyenne TT, Bura-Rivière A, Vaidyanathan S, Camisasca RP (2004) Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption. J Am Soc Nephrol 15(12):3126–3133PubMedCrossRefGoogle Scholar
  11. 11.
    Oparil S, Yarows SA, Patel S, Fang H, Zhang J, Satlin A (2007) Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet 370:221–229 (Erratum in: Lancet 370(9598):1542, (2007))PubMedCrossRefGoogle Scholar
  12. 12.
    ONTARGET Investigators, Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Telmisartan AC (2008) Ramipril, or both in patients at high risk for vascular events. N Engl J Med 358(15):1547–1559Google Scholar
  13. 13.
    McMurray JJ, Abraham WT, Dickstein K, Køber L, Massie BM, Aliskiren KH (2012) ALTITUDE, and the implications for ATMOSPHERE. Eur J Heart Fail 14(4):341–343Google Scholar
  14. 14.
    Meier P, Maillard MP, Meier JR, Tremblay S, Gauthier T, Burnier M (2011) Combining blockers of the renin-angiotensin system or increasing the dose of an angiotensin II receptor antagonist in proteinuric patients: a randomized triple-crossover study. J Hypertens 29(6):1228–1235PubMedCrossRefGoogle Scholar
  15. 15.
    Stergiou GS, Makris T, Papavasiliou M, Efstathiou S, Manolis A (2005) Comparison of antihypertensive effects of an angiotensin-converting enzyme inhibitor, a calcium antagonist and a diuretic in patients with hypertension not controlled by angiotensin receptor blocker monotherapy. J Hypertens 23(4):883–889PubMedCrossRefGoogle Scholar
  16. 16.
    Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O’Brien E, Ostergren J (2005) ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian cardiac outcomes trial-blood pressure lowering arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 366(9489):895–906PubMedCrossRefGoogle Scholar
  17. 17.
    Jamerson K, Weber MA, Bakris GL, Dahlöf B, Pitt B, Shi V, Hester A, Gupte J, Gatlin M, Velazquez EJ (2008) ACCOMPLISH trial investigators benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 359(23):2417–2428PubMedCrossRefGoogle Scholar
  18. 18.
    Gupta AK, Nasothimiou EG, Chang CL, Sever PS, Dahlöf B, Poulter NR (2011) ASCOT investigators. Baseline predictors of resistant hypertension in the Anglo-Scandinavian cardiac outcome trial (ASCOT): a risk score to identify those at high-risk. J Hypertens 29(10):2004–2013PubMedCrossRefGoogle Scholar
  19. 19.
    Rossat J, Maillard M, Nussberger J, Brunner HR, Burnier M (1999) Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects. Clin Pharmacol Ther 66(1):76–84PubMedCrossRefGoogle Scholar
  20. 20.
    Morgan T, Anderson A (2003) The effect of nonsteroidal anti-inflammatory drugs on blood pressure in patients treated with different antihypertensive drugs. J Clin Hypertens 5(1):53–57CrossRefGoogle Scholar
  21. 21.
    Fricker AF, Nussberger J, Meilenbrock S, Brunner HR, Burnier M (1998) Effect of indomethacin on the renal response to angiotensin II receptor blockade in healthy subjects. Kidney Int 54(6):2089–2097PubMedCrossRefGoogle Scholar
  22. 22.
    Lubianca JN, Faccin CS, Fuchs FD (2003) Oral contraceptives: a risk factor for uncontrolled blood pressure among hypertensive women. Contraception 67(1):19–24PubMedCrossRefGoogle Scholar
  23. 23.
    Weir MR, Chrysant SG, McCarron DA, Canossa-Terris M, Cohen JD, Gunter PA, Lewin AJ, Mennella RF, Kirkegaard LW, Hamilton JH, Weinberger MH, Weder AB (1998) Influence of race and dietary salt on the antihypertensive efficacy of an angiotensin-converting enzyme inhibitor or a calcium channel antagonist in salt-sensitive hypertensives. Hypertension 31(5):1088–1096PubMedCrossRefGoogle Scholar
  24. 24.
    Pimenta E, Gaddam KK, Oparil S, Aban I, Husain S, Dell’Italia LJ, Calhoun DA (2009) Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: results from a randomized trial. Hypertension 54(3):475–481PubMedCrossRefGoogle Scholar
  25. 25.
    Peterzan MA, Hardy R, Chaturvedi N, Hughes AD (2012) Meta-analysis of dose-response relationships for hydrochlorothiazide, chlorthalidone, and bendroflumethiazide on blood pressure, serum potassium, and urate. Hypertension 59(6):1104–1109PubMedCrossRefGoogle Scholar
  26. 26.
    Roush GC, Holford TR, Guddati AK (2012) Chlorthalidone compared with hydrochlorothiazide in reducing cardiovascular events: systematic review and network meta-analyses. Hypertension 59(6):1110–1117PubMedCrossRefGoogle Scholar
  27. 27.
    Ernst ME, Carter BL, Goerdt CJ, Steffensmeier JJ, Phillips BB, Zimmerman MB, Bergus GR (2006) Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension 47(3):352–358PubMedCrossRefGoogle Scholar
  28. 28.
    Bakris GL, Sica D, White WB, Cushman WC, Weber MA, Handley A, Song E, Kupfer S (2012) Antihypertensive efficacy of hydrochlorothiazide versus chlorthalidone combined with azilsartan medoxomil. Am J Med [Epub ahead of print]Google Scholar
  29. 29.
    Na KY, Oh YK, Han JS, Lee JS, Earm JH, Knepper MA, Kim GH (2003) Upregulation of Na+ transporter abundances in response to chronic thiazide or loop diuretic treatment in rats. Am J Physiol Renal Physiol 284:F133–F143PubMedGoogle Scholar
  30. 30.
    Nielsen J, Kwon TH, Masilamani S, Beutler K, Hager H, Nielsen S, Knepper MA (2002) Sodium transporter abundance profiling in kidney: effect of spironolactone. Am J Physiol Renal Physiol 283:F923–F933PubMedGoogle Scholar
  31. 31.
    Knauf H, Mutschler E (1997) Sequential nephron blockade breaks resistance to diuretics in edematous states. J Cardiovasc Pharmacol 29:367–372PubMedCrossRefGoogle Scholar
  32. 32.
    Bobrie G, Frank M, Azizi M, Peyrard S, Boutouyrie P, Chatellier G, Laurent S, Menard J, Plouin PF (2012) Sequential nephron blockade versus sequential renin-angiotensin system blockade in resistant hypertension: a prospective, randomized, open blinded endpoint study. J Hypertens 30(8):1656–1664PubMedCrossRefGoogle Scholar
  33. 33.
    de la Sierra A, Segura J, Banegas JR, Gorostidi M, de la Cruz JJ, Armario P, Oliveras A, Ruilope LM (2011) Clinical features of 8,295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension 57(5):898–902PubMedCrossRefGoogle Scholar
  34. 34.
    Martins LC, Figueiredo VN, Quinaglia T, Boer-Martins L, Yugar-Toledo JC, Martin JF, Demacq C, Pimenta E, Calhoun DA, Moreno H Jr (2011) Characteristics of resistant hypertension: ageing, body mass index, hyperaldosteronism, cardiac hypertrophy and vascular stiffness. J Hum Hypertens 25(9):532–538PubMedCrossRefGoogle Scholar
  35. 35.
    Gaddam KK, Nishizaka MK, Pratt-Ubunama MN, Pimenta E, Aban I, Oparil S, Calhoun DA (2008) Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion. Arch Intern Med 168(11):1159–1164PubMedCrossRefGoogle Scholar
  36. 36.
    Bochud M, Nussberger J, Bovet P, Maillard MR, Elston RC, Paccaud F, Shamlaye C, Burnier M (2006) Plasma aldosterone is independently associated with the metabolic syndrome. Hypertension 48(2):239–245PubMedCrossRefGoogle Scholar
  37. 37.
    Pimenta E, Gaddam KK, Pratt-Ubunama MN, Nishizaka MK, Cofield SS, Oparil S, Calhoun DA (2007) Aldosterone excess and resistance to 24-h blood pressure control. J Hypertens 25(10):2131–2137PubMedCrossRefGoogle Scholar
  38. 38.
    Dahlof B, Sever PS, Poulter NR et al (2005) Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian cardiac outcomes trial-blood pressure lowering arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet 366:895–906PubMedCrossRefGoogle Scholar
  39. 39.
    Chapman N, Dobson J, Wilson S, Dahlöf B, Sever PS, Wedel H, Poulter NR (2007) Anglo-Scandinavian cardiac outcomes trial investigators. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 49(4):839–845PubMedCrossRefGoogle Scholar
  40. 40.
    Engbaek M, Hjerrild M, Hallas J, Jacobsen IA (2010) The effect of low-dose spironolactone on resistant hypertension. J Am Soc Hypertens 4(6):290–294PubMedCrossRefGoogle Scholar
  41. 41.
    Alvarez–Alvarez B, Abad-Cardiel M, Fernandez-Cruz A, Martell-Claros N (2010) Management of resistant arterial hypertension: role of spironolactone versus double blockade of the renin-angiotensin-aldosterone system. J Hypertens 28(11):2329–2335PubMedCrossRefGoogle Scholar
  42. 42.
    Ouzan J, Perault C, Lincoff AM, Carre E, Mertes M (2002) The role of spironolactone in the treatment of patients with refractory hypertension. Am J Hypertens 15:333–339PubMedCrossRefGoogle Scholar
  43. 43.
    Nishizaka MK, Zaman MA, Calhoun DA (2003) Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens 16:925–930PubMedCrossRefGoogle Scholar
  44. 44.
    Sharabi Y, Adler E, Shamis A, Nussinovitch N, Markovitz A, Grossman E (2006) Efficacy of add-on aldosterone receptor blocker in uncontrolled hypertension. Am J Hypertens 19:750–755PubMedCrossRefGoogle Scholar
  45. 45.
    Lane DA, Shah S, Beevers DG (2007) Low-dose spironolactone in the management of resistant hypertension: a surveillance study. J Hypertens 25:891–894PubMedCrossRefGoogle Scholar
  46. 46.
    de Souza F, Muxfeldt E, Fiszman R, Salles G (2010) Efficacy of spironolactone therapy in patients with true resistant hypertension. Hypertension 55:147–152PubMedCrossRefGoogle Scholar
  47. 47.
    Gaddam K, Pimenta E, Thomas SJ, Cofield SS, Oparil S, Harding SM, Calhoun DA (2010) Spironolactone reduces severity of obstructive sleep apnoea in patients with resistant hypertension: a preliminary report. J Hum Hypertens 24(8):532–537PubMedCrossRefGoogle Scholar
  48. 48.
    Václavík J, Sedlák R, Plachy M, Navrátil K, Plásek J, Jarkovsky J, Václavík T, Husár R, Kociánová E, Táborsky M (2011) Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial. Hypertension 57(6):1069–1075PubMedCrossRefGoogle Scholar
  49. 49.
    Pathak A, Girerd X, Azizi M, Benamer H, Halimi JM, Lantelme P, Lefèvre T, Sapoval M (2012) French society of hypertension; French society of cardiology; working group on atheroma, interventional cardiology; French society of radiology. Expert consensus: renal denervation for the treatment of arterial hypertension. Arch Cardiovasc Dis 105(6–7):386–393PubMedGoogle Scholar
  50. 50.
    Vrijens B, Vincze G, Kristanto P, Urquhart J, Burnier M (2008) Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ 336(7653):1114–1117PubMedCrossRefGoogle Scholar
  51. 51.
    Shi L, Liu J, Koleva Y, Fonseca V, Kalsekar A, Pawaskar M (2010) Concordance of adherence measurement using self-reported adherence questionnaires and medication monitoring devices. Pharmacoeconomics 28(12):1097–1107PubMedCrossRefGoogle Scholar
  52. 52.
    Hamilton GA (2003) Measuring adherence in a hypertension clinical trial. Eur J Cardiovasc Nurs 2(3):219–228PubMedCrossRefGoogle Scholar
  53. 53.
    Burnier M, Schneider MP, Chioléro A, Stubi CL, Brunner HR (2001) Electronic compliance monitoring in resistant hypertension: the basis for rational therapeutic decisions. J Hypertens 19(2):335–341PubMedCrossRefGoogle Scholar
  54. 54.
    Weber MA, Black H, Bakris G, Krum H, Linas S, Weiss R, Linseman JV, Wiens BL, Warren MS, Lindholm LH (2009) A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial. Lancet 374(9699):1423–1431PubMedCrossRefGoogle Scholar
  55. 55.
    Bakris GL, Lindholm LH, Black HR, Krum H, Linas S, Linseman JV, Arterburn S, Sager P, Weber M (2010) Divergent results using clinic and ambulatory blood pressures: report of a darusentan-resistant hypertension trial. Hypertension 56(5):824–830PubMedCrossRefGoogle Scholar
  56. 56.
    Black HR, Bakris GL, Weber MA, Weiss R, Shahawy ME, Marple R, Tannoury G, Linas S, Wiens BL, Linseman JV, Roden R, Gerber MJ (2007) Efficacy and safety of darusentan in patients with resistant hypertension: results from a randomized, double-blind, placebo-controlled dose-ranging study. J Clin Hypertens (Greenwich) 9(10):760–769CrossRefGoogle Scholar
  57. 57.
    Symplicity HTN-2 Investigators, Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Böhm M (2010) Renal sympathetic denervation in patients with treatment-resistant hypertension (the simplicity HTN-2 Trial): a randomised controlled trial. Lancet 376(9756):1903–1909Google Scholar

Copyright information

© Springer-Verlag Italia 2013

Authors and Affiliations

  • Michel Burnier
    • 1
  • Antoinette Pechère Bertschi
    • 2
  • Gregoire Wuerzner
    • 1
  1. 1.Service of Nephrology and HypertensionUniversity HospitalLausanneSwitzerland
  2. 2.Unit of Hypertension, Departments of Specialties of Medicine and Community Medicine and Primary Care and Emergency MedicineUniversity HospitalGenevaSwitzerland

Personalised recommendations